Shunting for idiopathic normal pressure hydrocephalus.

IF 8.8 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Cochrane Database of Systematic Reviews Pub Date : 2024-08-06 DOI:10.1002/14651858.CD014923.pub2
Ronald K B Pearce, Anastasia Gontsarova, Davina Richardson, Abigail M Methley, Hilary Clare Watt, Kevin Tsang, Christopher Carswell
{"title":"Shunting for idiopathic normal pressure hydrocephalus.","authors":"Ronald K B Pearce, Anastasia Gontsarova, Davina Richardson, Abigail M Methley, Hilary Clare Watt, Kevin Tsang, Christopher Carswell","doi":"10.1002/14651858.CD014923.pub2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Normal pressure hydrocephalus (NPH) occurs when the brain ventricles expand, causing a triad of gait, cognitive, and urinary impairment. It can occur after a clear brain injury such as trauma, but can also occur without a clear cause (termed idiopathic, or iNPH). Non-randomised studies have shown a benefit from surgically diverting ventricular fluid to an area of lower pressure by cerebrospinal fluid (CSF)-shunting in iNPH, but historically there have been limited randomised controlled trial (RCT) data to confirm this.</p><p><strong>Objectives: </strong>To determine the effect of CSF-shunting versus no CSF-shunting in people with iNPH and the frequency of adverse effects of CSF-shunting in iNPH.</p><p><strong>Search methods: </strong>We searched the Cochrane Dementia and Cognitive Improvement Group's register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), CINAHL (EBSCOhost), Web of Science Core Collection (Clarivate), LILACS (BIREME), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform on 15 February 2023.</p><p><strong>Selection criteria: </strong>We included only RCTs of people who had symptoms of gait, cognitive, or urinary impairment with communicating hydrocephalus (Evans index of > 0.3) and normal CSF pressure. Control groups included those with no CSF shunts or those with CSF shunts that were in 'inactive' mode.</p><p><strong>Data collection and analysis: </strong>We used standard Cochrane methodological procedures. Where necessary, we contacted study authors requesting data not provided in the papers. We assessed the overall certainty of the evidence using GRADE.</p><p><strong>Main results: </strong>We included four RCTs, of which three were combined in a meta-analysis. The four RCTs included 140 participants (73 with immediate CSF-shunting and 67 controls who had delayed CSF-shunting) with an average age of 75 years. Risk of bias was low in all parallel-group outcomes evaluated apart from gait speed, cognitive function (general cognition and Symbol Digit Test) (some concerns) and adverse events, which were not blind-assessed. CSF-shunting probably improves gait speed at less than six months post-surgery (standardised mean difference (SMD) 0.62, 95% confidence interval (CI) 0.24 to 0.99; 3 studies, 116 participants; moderate-certainty evidence). CSF-shunting may improve qualitative gait function at less than six months post-surgery by an uncertain amount (1 study, 88 participants; low-certainty evidence). CSF-shunting probably results in a large reduction of disability at less than six months post-surgery (risk ratio 2.08, 95% CI 1.31 to 3.31; 3 studies, 118 participants; moderate-certainty evidence). The evidence is very uncertain about the effect of CSF-shunting on cognitive function at less than six months post-CSF-shunt surgery (SMD 0.35, 95% CI -0.04 to 0.74; 2 studies, 104 participants; very low-certainty evidence). The evidence is also very uncertain about the effect of CSF-shunt surgery on adverse events (1 study, 88 participants; very low-certainty evidence). There were no data regarding the effect of CSF-shunting on quality of life.</p><p><strong>Authors' conclusions: </strong>We found moderate-certainty evidence that CSF-shunting likely improves gait speed and disability in iNPH in the relative short term. The evidence is very uncertain regarding cognition and adverse events. There were no longer-term RCT data for any of our prespecified outcomes. More studies are required to improve the certainty of these findings. In addition, more information is required regarding patient ethnicity and the effect of CSF-shunting on quality of life.</p>","PeriodicalId":10473,"journal":{"name":"Cochrane Database of Systematic Reviews","volume":"8 ","pages":"CD014923"},"PeriodicalIF":8.8000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301990/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cochrane Database of Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/14651858.CD014923.pub2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Normal pressure hydrocephalus (NPH) occurs when the brain ventricles expand, causing a triad of gait, cognitive, and urinary impairment. It can occur after a clear brain injury such as trauma, but can also occur without a clear cause (termed idiopathic, or iNPH). Non-randomised studies have shown a benefit from surgically diverting ventricular fluid to an area of lower pressure by cerebrospinal fluid (CSF)-shunting in iNPH, but historically there have been limited randomised controlled trial (RCT) data to confirm this.

Objectives: To determine the effect of CSF-shunting versus no CSF-shunting in people with iNPH and the frequency of adverse effects of CSF-shunting in iNPH.

Search methods: We searched the Cochrane Dementia and Cognitive Improvement Group's register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), CINAHL (EBSCOhost), Web of Science Core Collection (Clarivate), LILACS (BIREME), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform on 15 February 2023.

Selection criteria: We included only RCTs of people who had symptoms of gait, cognitive, or urinary impairment with communicating hydrocephalus (Evans index of > 0.3) and normal CSF pressure. Control groups included those with no CSF shunts or those with CSF shunts that were in 'inactive' mode.

Data collection and analysis: We used standard Cochrane methodological procedures. Where necessary, we contacted study authors requesting data not provided in the papers. We assessed the overall certainty of the evidence using GRADE.

Main results: We included four RCTs, of which three were combined in a meta-analysis. The four RCTs included 140 participants (73 with immediate CSF-shunting and 67 controls who had delayed CSF-shunting) with an average age of 75 years. Risk of bias was low in all parallel-group outcomes evaluated apart from gait speed, cognitive function (general cognition and Symbol Digit Test) (some concerns) and adverse events, which were not blind-assessed. CSF-shunting probably improves gait speed at less than six months post-surgery (standardised mean difference (SMD) 0.62, 95% confidence interval (CI) 0.24 to 0.99; 3 studies, 116 participants; moderate-certainty evidence). CSF-shunting may improve qualitative gait function at less than six months post-surgery by an uncertain amount (1 study, 88 participants; low-certainty evidence). CSF-shunting probably results in a large reduction of disability at less than six months post-surgery (risk ratio 2.08, 95% CI 1.31 to 3.31; 3 studies, 118 participants; moderate-certainty evidence). The evidence is very uncertain about the effect of CSF-shunting on cognitive function at less than six months post-CSF-shunt surgery (SMD 0.35, 95% CI -0.04 to 0.74; 2 studies, 104 participants; very low-certainty evidence). The evidence is also very uncertain about the effect of CSF-shunt surgery on adverse events (1 study, 88 participants; very low-certainty evidence). There were no data regarding the effect of CSF-shunting on quality of life.

Authors' conclusions: We found moderate-certainty evidence that CSF-shunting likely improves gait speed and disability in iNPH in the relative short term. The evidence is very uncertain regarding cognition and adverse events. There were no longer-term RCT data for any of our prespecified outcomes. More studies are required to improve the certainty of these findings. In addition, more information is required regarding patient ethnicity and the effect of CSF-shunting on quality of life.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
特发性正常压力脑积水的分流术。
背景:正常压力脑积水(NPH)是指脑室扩张,导致步态、认知和排尿功能障碍的三联征。它可能发生在明确的脑损伤(如外伤)之后,也可能在没有明确病因的情况下发生(称为特发性或 iNPH)。非随机研究显示,通过脑脊液(CSF)分流手术将脑室积液分流到压力较低的区域对 iNPH 有好处,但历史上只有有限的随机对照试验(RCT)数据证实了这一点:确定脑脊液分流与不进行脑脊液分流对 iNPH 患者的影响,以及脑脊液分流在 iNPH 中的不良反应频率:我们检索了 Cochrane 痴呆与认知改善小组的登记簿、Cochrane 对照试验中央登记簿 (CENTRAL)、MEDLINE (Ovid SP)、Embase (Ovid SP)、PsycINFO (Ovid SP)、CINAHL (EBSCOhost)、Web of Science Core Collection (Clarivate)、LILACS (BIREME)、ClinicalTrials.gov 和世界卫生组织国际临床试验登记平台(截至 2023 年 2 月 15 日):我们仅纳入了针对有步态、认知或排尿障碍症状,伴有交流性脑积水(埃文斯指数大于 0.3)且 CSF 压力正常的患者的 RCT。对照组包括未进行脑脊液分流或脑脊液分流处于 "非活动 "状态的患者:我们采用了标准的 Cochrane 方法学程序。必要时,我们联系了研究作者,要求其提供论文中未提供的数据。我们使用 GRADE 评估了证据的总体确定性:我们纳入了四项研究性试验,其中三项合并进行了荟萃分析。这四项研究共纳入 140 名参与者(73 名立即进行 CSF 分流,67 名对照者延迟进行 CSF 分流),平均年龄为 75 岁。除了步态速度、认知功能(一般认知和符号数字测试)(存在一些问题)和不良事件(未进行盲法评估)外,所有平行组结果的偏倚风险都很低。脑脊液分流术可能会改善术后不到六个月的步态速度(标准化平均差异(SMD)0.62,95% 置信区间(CI)0.24 至 0.99;3 项研究,116 名参与者;中度确定性证据)。脑脊液分流术可改善术后不到六个月的步态功能,但改善程度不确定(1 项研究,88 名参与者;低度确定性证据)。CSF 分流术可能会在术后不到六个月的时间内大幅降低残疾程度(风险比 2.08,95% CI 1.31 至 3.31;3 项研究,118 名参与者;中度确定性证据)。关于CSF分流术后不到六个月时CSF分流对认知功能的影响,证据非常不确定(SMD为0.35,95% CI为-0.04至0.74;2项研究,104名参与者;极低确定性证据)。关于 CSF 分流手术对不良事件的影响,证据也很不确定(1 项研究,88 名参与者;证据确定性很低)。没有关于脑脊液分流术对生活质量影响的数据:作者的结论:我们发现中度确定性证据表明,CSF 分流术可能在相对短期内改善 iNPH 患者的步速和残疾状况。关于认知能力和不良事件的证据非常不确定。在我们预设的结果中,没有任何长期 RCT 数据。需要更多的研究来提高这些结果的确定性。此外,还需要更多有关患者种族和 CSF 分流对生活质量影响的信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.60
自引率
2.40%
发文量
173
审稿时长
1-2 weeks
期刊介绍: The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.
期刊最新文献
Time to publication for results of clinical trials. Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery. Psychotherapeutic treatments for depression in older adults. Excisional surgery versus ablative surgery for ovarian endometrioma. Inotropes for the prevention of low cardiac output syndrome and mortality for paediatric patients undergoing surgery for congenital heart disease: a network meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1